RecruitingPhase 4NCT04130464

Intraperitoneal Infusion of Analgesic for Postoperative Pain Management

The Impact of the Continuous Infusion of Intraperitoneal Analgesics on Postoperative Pain After Minimally Invasive Hysterectomy: a Randomized Controlled Trial


Sponsor

Ying Liu

Enrollment

120 participants

Start Date

Sep 30, 2019

Study Type

INTERVENTIONAL

Conditions

Summary

The study is a prospective, double-blinded, placebo-controlled multi-center trial to measure if postoperative pain and the amount of narcotics used are reduced by a clinically significant amount in women undergoing minimally invasive hysterectomy receiving a continuous infusion of intraperitoneal (IP) local anesthetic (LA) or a continuous infusion of LA combined with an NSAID compared with a control group who receives only 0.9% normal saline.


Eligibility

Sex: FEMALEMin Age: 18 YearsMax Age: 65 Years

Inclusion Criteria5

  • Hysterectomy planned for a benign gynecologic reason (no evidence of, or concern for, malignancy in the cervix, uterus, tubes or ovaries. Benign gynecologic reasons to have a hysterectomy include fibroids, abnormal uterine bleeding, endometriosis, and pelvic pain.)
  • Patient is scheduled to have surgery with a fellowship trained minimally invasive gynecologic surgeons at one of the study sites.
  • Patient is planned for a robotic assisted total laparoscopic hysterectomy (RA-TLH) or a total laparoscopic hysterectomy (TLH).
  • Patient is capable of informed consent.
  • Patient is capable of completing the questionnaires.

Exclusion Criteria4

  • Concern for malignancy
  • The procedure is scheduled outside MIGS department.
  • Allergy to any study related medication (i.e. Ketorolac and Ropivacaine)
  • Patient is enrolled in another pain management study.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGRopivacaine Infusion from ON-Q Pump

Infusion of 0.2% ropivacaine at 8 mL/hour for 72 hours

DRUGRopivacaine + Ketorolac Infusion from ON-Q Pump

Infusion of 0.2% ropivacaine + 30 mg ketorolac at 8 mL/hour for 72 hours

DRUGNormal Saline Infusion from ON-Q Pump

Infusion of 0.9% normal saline at 8 mL/hour for 72 hours


Locations(2)

MedStar Washington Hospital Center

Washington D.C., District of Columbia, United States

The GW Medical Faculty Associates

Washington D.C., District of Columbia, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04130464


Related Trials